VeriSIM Life has launched a pharmaceutical subsidiary called PulmoSIM Therapeutics (PulmoSIM) to search for new treatments for rare lung diseases. Using artificial intelligence, PulmoSIM’s goal is to assess which therapies previously approved by the U.S. Food and Drug Administration for certain conditions can be effective for the treatment of…
A modified protein called citrullinated vimentin (cit-vim), released by immune cells in response to harmful pollutants, may contribute to lung scarring in people with idiopathic pulmonary fibrosis (IPF), a study reports. These findings suggest that cadmium and carbon black, which can be found in cigarette smoke as well as…
The University of Pittsburgh School of Medicine and Yale University School of Medicine were selected to join the Three Lakes Consortium for Pulmonary Fibrosis to help advance the development of new treatments for pulmonary fibrosis (PF). As part of the consortium, both universities will be collaborating with…
The key topics of discussion during a new webinar for people with pulmonary fibrosis (PF) focused on strategies — ranging from getting appropriate vaccines and managing individual symptoms to taking advantage of palliative and support care — for improving patient quality of life. The talk was given by Marlies…
Next month is the five-year anniversary of when I first heard the words “idiopathic pulmonary fibrosis.” I was diagnosed by a pulmonologist at a local respiratory care center, where I’d finally been referred after 13 months of dealing with persistent shortness of breath, dry cough, and fatigue. I try…
CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…
Galecto was advised to stop enrolling and treating patients at high dose and certain ones at low dose in its Phase 2b GALACTIC-1 trial of GB0139, an investigational inhaled therapy for idiopathic pulmonary fibrosis (IPF). The recommendation — made by an independent data safety and monitoring board (DSMB) that…
Suppressing MDM4, a mechanosensitive protein produced by myofibroblasts — the main drivers of pulmonary fibrosis (PF) — promoted the death and clearance of myofibroblasts and reversed persistent lung scarring in a mouse model, a study shows. Notably, these benefits were associated with a reduced stiffness of the extracellular matrix (ECM),…
I have mixed feelings about getting the COVID-19 vaccine. It’s not what you might expect, though. I am not conflicted about whether I should get it. I am not afraid or suspicious of it. I don’t think the vaccine’s fast creation makes it unreliable or unpredictable — merely unprecedented.
Tiny particles, or nanoparticles, coated with a peptide called GSE4 prevented some features of idiopathic pulmonary fibrosis (IPF) and eased others in a rat model of this disease, scientists report. No harmful effects were associated with the use of these GSE4-loaded nanoparticles in the animals, the team added, suggesting they should…
Get regular updates to your inbox.
